WeLeader Biomedical Co., Ltd. (TPEX:7713)
Taiwan
· Delayed Price · Currency is TWD 70.20
-0.80 (-1.13%)
At close: Mar 6, 2026
WeLeader Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1,109 | 991.13 | 940.7 | 1,036 | 841.14 |
| Revenue Growth (YoY) | 11.92% | 5.36% | -9.17% | 23.13% | - |
| Cost of Revenue | 738.33 | 674.8 | 642.62 | 743.97 | 622.22 |
| Gross Profit | 370.97 | 316.32 | 298.08 | 291.75 | 218.92 |
| Selling, General & Admin | 109.84 | 102.13 | 100.59 | 97.64 | 86.26 |
| Operating Expenses | 109.74 | 102.19 | 100.12 | 97.11 | 86.65 |
| Operating Income | 261.22 | 214.14 | 197.96 | 194.64 | 132.28 |
| Interest Expense | -8.02 | -5.8 | -5.69 | -4.21 | -6.16 |
| Interest & Investment Income | 2.98 | 1.29 | 0.59 | 0.24 | 0.08 |
| Other Non Operating Income (Expenses) | 4.8 | 5.2 | 2.27 | 1.88 | 4.85 |
| EBT Excluding Unusual Items | 260.98 | 214.83 | 195.13 | 192.54 | 131.04 |
| Gain (Loss) on Sale of Investments | - | 0.4 | 0.1 | -0.68 | 0.01 |
| Gain (Loss) on Sale of Assets | - | -0.02 | -1.69 | 0.69 | 0.41 |
| Pretax Income | 260.98 | 215.21 | 193.55 | 192.55 | 131.46 |
| Income Tax Expense | 52.43 | 44.99 | 41.26 | 38.75 | 25.69 |
| Net Income | 208.56 | 170.21 | 152.28 | 153.8 | 105.77 |
| Net Income to Common | 208.56 | 170.21 | 152.28 | 153.8 | 105.77 |
| Net Income Growth | 22.53% | 11.77% | -0.98% | 45.40% | - |
| Shares Outstanding (Basic) | 45 | 42 | 41 | 30 | 28 |
| Shares Outstanding (Diluted) | 46 | 42 | 41 | 30 | 28 |
| Shares Change (YoY) | 10.61% | 1.55% | 35.00% | 8.28% | - |
| EPS (Basic) | 4.64 | 4.09 | 3.74 | 5.13 | 3.79 |
| EPS (Diluted) | 4.52 | 4.08 | 3.71 | 5.05 | 3.76 |
| EPS Growth | 10.78% | 9.97% | -26.53% | 34.31% | - |
| Free Cash Flow | 100.56 | 108.06 | 117.13 | -379.09 | 216.43 |
| Free Cash Flow Per Share | 2.18 | 2.59 | 2.85 | -12.46 | 7.70 |
| Dividend Per Share | - | 3.368 | 2.300 | 0.860 | 0.450 |
| Dividend Growth | - | 46.43% | 167.44% | 91.11% | - |
| Gross Margin | 33.44% | 31.92% | 31.69% | 28.17% | 26.03% |
| Operating Margin | 23.55% | 21.61% | 21.04% | 18.79% | 15.73% |
| Profit Margin | 18.80% | 17.17% | 16.19% | 14.85% | 12.57% |
| Free Cash Flow Margin | 9.06% | 10.90% | 12.45% | -36.60% | 25.73% |
| EBITDA | 385.38 | 242.96 | 227.58 | 226.65 | 165.64 |
| EBITDA Margin | 34.74% | 24.51% | 24.19% | 21.88% | 19.69% |
| D&A For EBITDA | 124.16 | 28.83 | 29.62 | 32.01 | 33.36 |
| EBIT | 261.22 | 214.14 | 197.96 | 194.64 | 132.28 |
| EBIT Margin | 23.55% | 21.61% | 21.04% | 18.79% | 15.73% |
| Effective Tax Rate | 20.09% | 20.91% | 21.32% | 20.13% | 19.54% |
Source: S&P Capital IQ. Standard template. Financial Sources.